Prognia
Drug Database
🇪🇺EU · EMAApplication withdrawnATC: S01EE03

Durysta(bimatoprost)

Glaucoma, Open-Angle;Ocular Hypertension

Marketing Authorisation Holder: AbbVie Deutschland GmbH & Co. KG

INN: bimatoprost

Indication

Indicated for the reduction of intraocular pressure (IOP) in adults with open angle glaucoma (OAG) or ocular hypertension (OHT) who are unsuitable for topical IOP-lowering medications.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Durysta — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.